Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 8/20 | 0.59 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.59 |
| ▸ | NPY1R | P25929 | 5/20 | 0.59 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.56 |
| ▸ | VIPR2 | P41587 | 5/20 | 0.55 |
| ▸ | VIPR1 | P32241 | 3/20 | 0.55 |
| ▸ | NPY2R | P49146 | 3/20 | 0.55 |
| ▸ | TFPI | P10646 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10005969 | 1.00 | NPY4R (0.59) | NPY4RNPY5RNPY1RKISS1RVIPR2 | |
| SCHEMBL10005986 | 1.00 | NPY4R (0.59) | NPY4RNPY5RNPY1RKISS1RVIPR2 | |
| SCHEMBL10006003 | 1.00 | NPY4R (0.59) | NPY4RNPY5RNPY1RKISS1RVIPR2 | |
| SCHEMBL10005993 | 0.99 | NPY4R (0.58) | NPY4RNPY5RNPY1RKISS1RVIPR2 | |
| SCHEMBL10006027 | 0.99 | NPY4R (0.58) | NPY4RNPY5RNPY1RKISS1RVIPR2 | |
| SCHEMBL10006025 | 0.98 | NPY4R (0.57) | NPY4RNPY5RNPY1RKISS1RVIPR2 | |
| SCHEMBL10005974 | 0.98 | NPY4R (0.57) | NPY4RNPY5RNPY1RKISS1RVIPR2 | |
| SCHEMBL10005978 | 0.98 | NPY4R (0.57) | NPY4RNPY5RNPY1RKISS1RVIPR2 | |
| SCHEMBL10006012 | 0.98 | KISS1R (0.60) | NPY4RNPY5RNPY1RKISS1RVIPR2 | |
| SCHEMBL10005984 | 0.98 | KISS1R (0.60) | NPY4RNPY5RNPY1RKISS1RVIPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2450374-B9 | PEPTIDE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2016-11-23 | — | — | EP | disclosed |
| US-9260500-B2 | Peptide and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-16 | — | — | US | disclosed |
| EP-2450374-B1 | PEPTIDE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-09-30 | — | — | EP | disclosed |
| US-20120172293-A1 | PEPTIDE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172293-A1 | PEPTIDE AND USE THEREOF | GLP1R, GIPR, SCTR | NPY4R 4/4885NPY5R 6/4885NPY1R 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.